
Optomed Q4 - Lower sales than anticipated, but a major catalyst is getting closer

Redeye provides an update in relation to Optomed's Q4 2023 report. The sales of EUR3.7m during the quarter were lower than anticipated. However, we learned that the additional data has been submitted to the FDA and that Optomed is one step closer to a potential approval. Based on the report, we have made some changes in our short-term estimates; however, the changes do not render an updated fair value range, including a base case of EUR7.5.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[Optomed Q4 - Lower sales than anticipated, but a major catalyst is getting closer](#)